- Home
- FOF vs SABS Comparison
FOF vs SABS Comparison
Compare FOF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOF | SABS |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.8M | 344.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FOF | SABS |
|---|---|---|
| Price | $12.34 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.64 |
| AVG Volume (30 Days) | 68.4K | ★ 731.9K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.12 | $2.10 |
| 52 Week High | $15.04 | $5.15 |
Technical Indicators
Market Signals| Indicator | FOF | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 27.41 |
| Support Level | $12.12 | N/A |
| Resistance Level | $12.60 | $4.04 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 50.30 | 13.16 |
Price Performance
Historical ComparisonAbout FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.